Evidence map›Paper›PMID 28780731›Full record

ReviewClinical reviews in allergy & immunology2018

Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Wolf-Henning Boehncke, Nicolo Costantino Brembilla

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Role of oxeiptosis in disease mechanisms and therapeutic opportunities.Apoptosis : an international journal on programmed cell death · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Pivotal Role of mTOR in Non-Skin Manifestations of Psoriasis.International journal of molecular sciences · 2024
    Review
  14. From the Skin to Distant Sites: T Cells in Psoriatic Disease.International journal of molecular sciences · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wolf-Henning BoehnckeDivison of Dermatology and Venerology, Geneva University Hospitals, Geneva, Switzerland. wolf-henning.boehncke@hcuge.ch.
Nicolo Costantino BrembillaDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_152680
6 · The paper itself

Abstract

In times of targeted therapies, innovative therapeutics become tools to further unravel the pathogenesis of the treated disease, thus influencing current pathogenetic concepts. Based on such paradigm shifts, the next generation of novel therapeutic targets might be identified. Psoriasis is a good example for the resulting most fruitful dialog between clinical and fundamental research. As a result of this, the key role of Th17 lymphocytes, some of their effector molecules, as well as mediators contributing to their maturation have been identified, many of these being targeted by some of the most effective drugs currently available to treat psoriasis. During this process, it became obvious that major parts of the puzzle remain yet to be uncovered or understood in much more detail. This review will therefore address the search for additional important effector cells other than Th17 lymphocytes, such as neutrophils, monocytes, and mast cells, mediators other than IL-17A, including some other IL-17 isoforms, and trigger factors such as potential autoantigens. This will lead to discussing the next generation of targeted therapies for psoriasis as well as treatment goals. These goals need to comprise both psoriasis as well as its comorbidities, as a comprehensive approach to manage the whole patient with all his health issues is urgently needed. Finally, given the substantial differences in resources available in different parts of the world, the global burden of psoriasis and options on how to care for patients outside developed countries will be assessed.

Indexed as

Health Services Needs and DemandAutoimmunityBiomarkersClinical Decision-MakingComorbidityCytokinesDisease ManagementDisease SusceptibilityHealth ResourcesHumansInflammation MediatorsInsulin ResistancePsoriasisSeverity of Illness IndexTh17 CellsBiomarkersCytokinesInflammation MediatorsComorbiditiesIL-17Insulin resistanceMinimal disease activityPathogenesisPsoriasisTreatment

Identifiers

PMID28780731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.